Myeloproliferative neoplasms
Chronic neutrophilic leukemia
Also called: CNL · CSF3R-mutated CNL · myeloproliferative neoplasm · MPN · BCR::ABL1-negative chronic neutrophilic leukemia
Classified by the World Health Organization as Chronic neutrophilic leukaemia.
What a donor has to do with this
For some people with this condition, a transplant using blood stem cells from an unrelated donor is part of the treatment guidelines. When a transplant is the right route and no one in the family matches, that donor comes from a registry. Not everyone with this condition has a transplant, and many never need one.
This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.
This page is not written out in full yet
We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.
What the evidence says
- Who it affects
- Typically diagnosed around age 65 and is markedly more common in men. Source population/region/year: international CNL literature synthesized in the Frontiers in Oncology review, published 2022.
- Treatments other than a transplant
- Hydroxyurea, interferon and ruxolitinib for CSF3R/JAK-STAT-driven disease; responses are often temporary and no non-HCT approach is established as curative
- If a transplant is used, the cells come from
- Allogeneic peripheral blood or bone marrow; matched unrelated donors predominate in one small Japanese nationwide series; cord-blood use was not reported in the opened disease-specific sources; dominant source not reported in the opened disease-specific sources
- How often the donor was unrelated
- Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.
Where this gets complicated
The exact donor-share estimate comes from a very small Japanese nationwide cohort and must not be generalized globally. Evidence is case-series level and older diagnostic criteria vary.
“Four patients received transplantation from matched-unrelated donors”
It describes what teams consider in general. It cannot say what applies to any one person. Read the source.
Registries need people
Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.
Related conditions
Others in myeloproliferative neoplasms. They are genuinely different diseases with different treatments — the group name is not a diagnosis.
Where this came from
- WHO Classification of Haematolymphoid Tumours, 5th edition — final table of contents — WHO/IARC, final print volume 2024; online classification introduced 2022
- Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management — Frontiers in Oncology, 2022-04-14
- Indications for haematopoietic cell transplantation and CAR-T: 2025 EBMT practice recommendations — EBMT / Bone Marrow Transplantation, 2025-09-09